RSV also strikes at the other end of life, causing more than 177,000 hospitalizations and 14,000 deaths among older adults annually. Despite decades of effort, the arsenal to fight RSV has so far included only one monoclonal antibody, given monthly to children at high risk for severe disease. There has never been a way to prevent RSV. But six drug companies are actively developing RSV vaccines or antibodies, suggesting this year could be the last one without adequate tools to fight the virus. Visit the link in bio to learn more.